

The Medical Letter[®]

on Drugs and Therapeutics

Volume 64

January 24, 2022

ISSUE No.

1642

IN THIS ISSUE

COVID-19 Updates.....p 16

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 64 (Issue 1642)

January 24, 2022

Take CME Exams

COVID-19 UPDATES

Pfizer-BioNTech COVID-19 Vaccine

On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (*Comirnaty*) to incorporate the following changes:

1. A third primary dose of the vaccine can now be given ≥ 28 days after the second to children 5-11 years old who have undergone solid organ transplantation or have an equivalent level of immune compromise.^{1,2}
2. Booster doses of the vaccine are now authorized for use in children 12-15 years old.^{1,3}
3. The length of time after completion of a primary series with the vaccine at which patients become eligible for booster immunization has been reduced from 6 months to 5 months.^{1,3}

On January 7, the FDA amended the EUA of the Moderna COVID-19 vaccine to shorten the interval between completion of a primary series and receipt of a booster dose from 6 months to 5 months.⁴

Booster Schedules – Patients can now receive a booster dose of a COVID-19 vaccine 5 months after completion of a primary series with the Pfizer-BioNTech or Moderna vaccine or 2 months after receiving a primary dose of the Johnson & Johnson/Janssen vaccine. ■

1. FDA News Release. Coronavirus (COVID-19) update: FDA takes multiple actions to expand use of Pfizer-BioNTech COVID-19 vaccine. January 3, 2022. Available at: <https://bit.ly/3qVaN18>. Accessed January 6, 2022.
2. FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). For 5-11 years of age. January 3, 2022. Available at: <https://bit.ly/3jX9xri>. Accessed January 6, 2022.
3. FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). For 12 years of age and older. January 3, 2022. Available at: <https://bit.ly/3bBH5GV>. Accessed January 6, 2022.
4. FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). January 7, 2022. Available at: <https://bit.ly/3nosylA>. Accessed January 7, 2022.

Monoclonal Antibodies for COVID-19

The anti-SARS-CoV-2 antibody combinations casirivimab plus imdevimab (*REGEN-COV*) and bamlanivimab plus etesevimab are not active against the Omicron variant of SARS-CoV-2. These antibodies remain available, however, through federal distribution. NIH guidelines state that their use can be considered in regions where the Delta variant still causes a significant proportion of COVID-19 cases if alternative drugs are unavailable or contraindicated.^{1,2}

Sotrovimab, which is authorized by the FDA for treatment of mild to moderate COVID-19 in patients ≥ 12 years old who weigh ≥ 40 kg and are at high risk of progressing to severe disease, is the only monoclonal antibody available in the US that has activity against the Omicron variant of SARS-CoV-2.^{2,3} ■

1. HHS Public Health Emergency. Updated guidelines regarding allocation of bamlanivimab/etesevimab and REGEN-COV therapeutics: states and territories can continue to order both products. December 31, 2021. Available at: <https://bit.ly/3sZHD3o>. Accessed January 6, 2022.
2. NIH. The COVID-19 Treatment Guidelines Panel's statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. December 30, 2021. Available at: <https://bit.ly/3EUXjHz>. Accessed January 6, 2022.
3. An EUA for sotrovimab for treatment of COVID-19. *Med Lett Drugs Ther* 2021; 63:97.

Additional Content Available Online: COVID-19 Charts

More information on vaccines and drugs for COVID-19 can be found in the COVID-19 Resources section of our website: www.medicalletter.org/drugs-for-covid-19.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
 www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
 please e-mail your request to:
 permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.

Get Connected:  

Copyright 2022. ISSN 1523-2859

The
 Medical
 Letter